ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota. The company went IPO on 2000-05-04. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Comment le bénéfice par action récent de ANIP se compare-t-il aux attentes ?
Le bénéfice par action le plus récent de ANI Pharmaceuticals Inc est de $2.33, battement les attentes de $2.03.
Comment les revenus de ANI Pharmaceuticals Inc ANIP se sont-ils comportés au dernier trimestre ?
Les revenus de ANI Pharmaceuticals Inc pour le dernier trimestre s'élèvent à $2.33
Quelle est l'estimation des revenus pour ANI Pharmaceuticals Inc ?
Selon 9 analystes de Wall Street, l'estimation des revenus de ANI Pharmaceuticals Inc varie de $253.79M à $192.47M
Quel est le score de qualité des bénéfices pour ANI Pharmaceuticals Inc ?
ANI Pharmaceuticals Inc a un score de qualité des bénéfices de B+/57.04402. Le score est basé sur quatre dimensions : rentabilité, croissance, génération de trésorerie et allocation de capital, et effet de levier.
Quand ANI Pharmaceuticals Inc publie-t-elle ses résultats ?
Le prochain rapport de résultats de ANI Pharmaceuticals Inc est attendu pour 2026-05-28
Quels sont les bénéfices attendus de ANI Pharmaceuticals Inc ?
Les bénéfices attendus de ANI Pharmaceuticals Inc s'élèvent à $236.16M, selon les analystes de Wall Street.
ANI Pharmaceuticals Inc a-t-elle dépassé les attentes en matière de bénéfices ?
Les bénéfices récents de ANI Pharmaceuticals Inc s'élèvent à $247.06M, battement les attentes.